Immunosuppression for ipilimumab-related toxicity can cause pneumocystis pneumonia but spare antitumor immune control

OncoImmunology

Volumn 4, Issue 10, 2015, Pages

  Arriola, Edurne ^a   Wheater, Matthew ^a   Krishnan, Radhika ^a   Smart, James ^a   Foria, Vipul ^a   Ottensmeier, Christian ^a  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

immunosuppression; infliximab; ipilimumab; melanoma; opportunistic; pneumocystis; pneumonia; steroids

Indexed keywords

COTRIMOXAZOLE; IMMUNOGLOBULIN G; INFLIXIMAB; IPILIMUMAB; PREDNISOLONE; STEROID;

ADULT; AGED; ARTICLE; BLURRED VISION; BRONCHOSCOPY; CAPILLARY LEAK SYNDROME; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DRUG DOSE REDUCTION; DRUG MEGADOSE; DYSPNEA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HYPOXIA; IMMUNOSUPPRESSIVE TREATMENT; LUNG METASTASIS; LYMPHOCYTE COUNT; MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; PERIPHERAL EDEMA; PNEUMOCYSTIS PNEUMONIA; SIGMOIDOSCOPY; SINGLE DRUG DOSE; THORAX PAIN; THROMBOCYTE COUNT; TUMOR IMMUNITY; VITRECTOMY;

EID: 84940688916     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1040218     Document Type: Article

References (15)

1. F.S.Hodi, S.J.O'Day, D.F.McDermott, R.W.Weber, J.A.Sosman, J.B.Haanen, R.Gonzalez, C.Robert, D.Schadendorf, J.C.Hassel et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
2. T.Powles, J.P.Eder, G.D.Fine, F.S.Braiteh, Y.Loriot, C.Cruz, J.Bellmunt, H.A.Burris, D.P.Petrylak, S.L.Teng et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515:558-62; PMID:25428503; http://dx.doi.org/10.1038/nature13904
3. J.S.Weber. Practical management of immune-related adverse events from immune checkpoint protein antibodies for the oncologist. Am Soc Clin Oncol Educ 2012; 174-7; PMID:24451730; http://dx.doi.org/10.14694/EdBook_AM.2012.32.174
4. L.A.Fecher, S.S.Agarwala, F.S.Hodi, J.S.Weber. Ipilimumab and its toxicities: a multidisciplinary approach. Oncologist 2013; 18:733-43; PMID:23774827; http://dx.doi.org/10.1634/theoncologist.2012-0483
5. S.G.Downey, J.A.Klapper, F.O.Smith, J.C.Yang, R.M.Sherry, R.E.Royal, U.S.Kammula, M.S.Hughes, T.E.Allen, C.L.Levy et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13:6681-8; PMID:17982122; http://dx.doi.org/10.1158/1078-0432.CCR-07-0187
6. J.D.Lord, R.C.Hackman, A.Moklebust, J.A.Thompson, C.S.Higano, D.Chielens, G.Steinbach, G.B.McDonald. Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci 2010; 55:1396-405; PMID:19507029; http://dx.doi.org/10.1007/s10620-009-0839-8
7. C.Kyi, M.D.Hellmann, J.D.Wolchok, P.B.Chapman, M.A.Postow. Opportunistic infections in patients treated with immunotherapy for cancer. J Immunother Cancer 2014; 2:19; PMID:24991413; http://dx.doi.org/10.1186/2051-1426-2-19
8. A.Morris, J.D.Lundgren, H.Masur, P.D.Walzer, D.L.Hanson, T.Frederick, L.Huang, C.B.Beard, J.E.Kaplan. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis 2004; 10:1713-20; PMID:15504255; http://dx.doi.org/10.3201/eid1010.030985
9. R.Maini, K.L.Henderson, E.A.Sheridan, T.Lamagni, G.Nichols, V.Delpech, N.Phin. Increasing Pneumocystis pneumonia, England, UK, 2000–2010. Emerg Infect Dis 2013; 19:386-92; PMID:23622345; http://dx.doi.org/10.3201/eid1903.121151
10. M.Zen, M.Canova, C.Campana, S.Bettio, L.Nalotto, M.Rampudda, R.Ramonda, L.Iaccarino, A.Doria. The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev 2011; 10:305-10; PMID:21224015; http://dx.doi.org/10.1016/j.autrev.2010.11.009
11. M.Wong, D.Ziring, Y.Korin, S.Desai, S.Kim, J.Lin, D.Gjertson, J.Braun, E.Reed, R.R.Singh. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008; 126:121-36; PMID:17916444; http://dx.doi.org/10.1016/j.clim.2007.08.013
12. T.Eddens, J.K.Kolls. Pathological and protective immunity to Pneumocystis infection. Semin Immunopathol. 2015;37(2):153–62; http://dx.doi.org/10.1007/s00281-014-0459-z
13. F.E.Lund, M.Hollifield, K.Schuer, J.L.Lines, T.D.Randall, B.A.Garvy. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006; 176:6147-54; PMID: 16670323; http://dx.doi.org/10.4049/jimmunol.176.10.6147
14. A.H.Limper, J.S.Hoyte, J.E.Standing. The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 1997; 99:2110-7; PMID:9151783; http://dx.doi.org/10.1172/JCI119384
15. P. Kvistborg, D.Philips, S.Kelderman, L.Hageman, C.Ottensmeier, D.Joseph-Pietras, M.J.Welters, S.van der Burg, E.Kapiteijn, O.Michielin et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 2014; 6:254ra128; PMID:25232180; http://dx.doi.org/10.1126/scitranslmed.3008918